

Children's Mercy Kansas City

SHARE @ Children's Mercy

Research Days

GME Research Days 2023

May 12th, 12:30 PM - 12:45 PM

Magnetic Resonance Image-Based Estimates of Hepatic Blood Flow In Children with and without Obesity; Implications For Physiologically-Based Pharmacokinetic Models

Yoon Cho

Children's Mercy Kansas City

Sherwin S. Chan

Children's Mercy Hospital

Chance S. Friesen

Children's Mercy Hospital

Valentina Shakhnovich

Children's Mercy Hospital

Let us know how access to this publication benefits you

Follow this and additional works at: <https://scholarlyexchange.childrensmercy.org/researchdays>



Part of the [Higher Education and Teaching Commons](#), [Medical Education Commons](#), [Pediatrics Commons](#), [Pharmaceutics and Drug Design Commons](#), [Physiological Processes Commons](#), and the [Science and Mathematics Education Commons](#)

Cho, Yoon; Chan, Sherwin S.; Friesen, Chance S.; and Shakhnovich, Valentina, "Magnetic Resonance Image-Based Estimates of Hepatic Blood Flow In Children with and without Obesity; Implications For Physiologically-Based Pharmacokinetic Models" (2023). *Research Days*. 13.

https://scholarlyexchange.childrensmercy.org/researchdays/GME_Research_Days_2023/ResearchDay5/13

This Oral Presentation is brought to you for free and open access by the Conferences and Events at SHARE @ Children's Mercy. It has been accepted for inclusion in Research Days by an authorized administrator of SHARE @ Children's Mercy. For more information, please contact hlsteel@cmh.edu.

MAGNETIC RESONANCE IMAGE-BASED ESTIMATES OF HEPATIC BLOOD FLOW IN CHILDREN WITH AND WITHOUT OBESITY; IMPLICATIONS FOR PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODELS

Cho,YY¹, Chan, SS^{1,2}, Friesen, C^{1,3}, Shakhnovich, V^{1,2}

¹Children's Mercy Kansas City; Kansas City, MO

²University of Missouri-Kansas City School of Medicine; Kansas City, MO

³University of Kansas School of Medicine; Kansas City, KS



Background

- Drug development process is complex, lengthy and expensive
- Clinical trials for demonstrating pediatric effectiveness can be difficult
- Dose optimization is complicated in pediatrics due to the differences in physiological processes
- Physiologically-based pharmacokinetic models (PBPK) have become indispensable in drug development and personalized dosing




Image Credit: Genome Research Limited

Background

- Physiologically-based pharmacokinetic models (PBPK) is a mathematical modeling approach
- Enables you to conduct simulations in representative virtual populations
- PBPK can be a powerful tool in understudied or vulnerable populations
- To achieve this, PBPK models require accurate physiological variability data in demographic and biological components within relevant subpopulations




Image credit: [https://jpharmsci.org/article/S0022-3549\(18\)30669-5/fulltext](https://jpharmsci.org/article/S0022-3549(18)30669-5/fulltext)

Background

- Our focus was on the liver where a majority of the drugs are metabolized or processed
- Two-dimensional (2D) phase-contrast MRI is a widely available, rapid technique, and validated method for the noninvasive measure of large vessel flow




Image Credit: Siemens-healthineers.com

Hypothesis

- Five anthropometric variables including age, height, weight, BMI-Z score, and liver volume can predict the hepatic blood flow.

Methods

- A prospective study at a single institution from July 2018-May 2022
- Volunteers were recruited from obesity clinic at the Center for Healthy Living
- Volunteers both with and without obesity were enrolled (n=69)
- Those with known systemic disease, such as cirrhosis, were excluded




Total Liver Blood Flow- Indirect Approach

Suprahepatic IVC


Infrahepatic IVC

Descending Aorta




Imaging Technique



IVC Flow Measurement



Descending Aorta Flow Measurement



Hepatic Blood Flow



Results

Median (Interquartile range)	
Age	14 (12-16)
Height (cm)	163.5 (155.1-172.0)
Weight (kg)	71.4 (60.2-98.4)
BMI-Z-score	1.8 (1.1-2.2)

Table 1. Patient Demographic Data

Weight class (n/%)	
Normal	17 (25%)
Overweight	23 (33%)
Obese	29 (42%)

Table 2. Weight class

Nonparametric Correlation (Spearman Correlation)

		Age	Height	Weight	BMI-Z score	Liver Volume
Blood Flow	Correlation Coefficient	0.204	0.431*	0.430*	0.229	0.408*
	Sig. (2 tailed)	0.093	0.000	0.000	0.064	0.001

*Correlation is significant at the 0.01 level (2-tailed)


Regression Coefficient for Predicting Hepatic Blood Flow

- Multivariable regression indicated about 30% of variability in Hepatic flow was explained by age, weight, height, and BMI Z score ($r^2 = 0.290$)

	Unstandardized coefficients		Standardized coefficients	t	Sig
	B	Std. Error	Beta		
AGE	-0.008	0.037	-0.043	-0.223	0.824
HEIGHT	0.010	0.009	0.215	1.118	0.268
WEIGHT	-0.001	0.007	-0.043	-0.122	0.904
BMI-Z score	0.010	0.129	0.019	0.077	0.939
Liver Volume	0.000	0.000	0.420	2.236	0.029


Results

- Liver volume displayed predictability of the Hepatic flow ($p = 0.029$; $B = 0.42$) while other variables remained constant



HBF for BMI-Z score

- Independent sample T-test showed statistically significant difference in hepatic blood flow between normal and obese weight classes (F = 4.924, P = 0.032)



Conclusion

- Study showed differences in hepatic blood flow in patients with or without obesity
 - Ultimately suggests that availability of the drug systematically is also different
- Hepatic blood flow correlated with height, weight, and liver volume, but our study showed that due to weak correlation and high variability, more direct method to measure hepatic blood flow is needed, which can be provided by 2D-phase contrast MRI

Future Considerations

- Focus on integrating the observed variability in hepatic blood flow into PBPK models for high extraction drugs (such as morphine, propofol, and verapamil), in order to assess net effect on accuracy of individual PK prediction
- Explore feasibility of MRI 2D blood flow data input into PBPK dashboard tool to predict precise individualized dosing

References

- Grimstein M, Yang Y, Zhang X, et al. Physiologically based pharmacokinetic modeling in regulatory science: an update from the U.S. Food and Drug Administration's Office of Clinical Pharmacology. *J Pharm Sci*. 2019;108:21-25.
- Joshi M, Dillman JR, Singh K, et al. Quantitative MRI of fatty liver disease in a large pediatric cohort: correlation between liver fat fraction, stiffness, volume, and patient-specific factors. *Abdom Radiol (NY)*. 2018;43(5):1168-1179.
- Frydrychowicz A, Roldan-Alzate A, Winslow E, et al. Comparison of radial 4D Flow-MRI with perivascular ultrasound to quantify blood flow in the abdomen and introduction of a porcine model of pre-hepatic portal hypertension. *Eur Radiol* 2017;27(12):5316–5324.
- Chouhan, M. D., Mookerjee, R. P., Bainbridge, A., Walker-Samuel, S., Davies, N., Halligan, S., ... Taylor, S. A. (2016). Use of caval subtraction 2d phase-contrast mr imaging to measure total liver and hepatic arterial blood flow: Preclinical validation and initial clinical translation. *Radiology*, 280(3), 916–923. <https://doi.org/10.1148/radiol.2016151832>.
- <https://www.pharmamirror.com/pharmaceutical-articles/regulatory-perspective-of-physiology-based-pharmacokinetic-pbpc-modeling/>

